NVN Liquidation Inc (fka NOVNQ)

[Milo2]

I think it's worthwhile pointing out why it cratered in early Jan --if better powered, the study would have probably been statistically significant and why they wanted to continue trialing it.

SB206 was statistically no better than placebo at fully clearing molluscum contagiosum in either trial, resulting in both studies missing their primary endpoints. That headline failure sent Novan’s stock into a tailspin.

However, Novan had a more positive take on the data, noting that, with a p-value of 0.062, one of the trials approached statistical significance. Tweaking the primary endpoint population, either by taking a per protocol approach or by changing the handling of missing data, brought the p-value down to below the threshold for statistical significance.

https://www.fiercebiotech.com/biotech/novan-crushed-by-phase-3-failures-antiviral-gel